Most Read Articles
Pearl Toh, 2 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
5 days ago
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.

Multidisciplinary therapy comparable to standard treatment for cutting cardiovascular markers in ACS

06 Dec 2019

Screening for obstructive sleep apnoea and multifaceted treatment during the subacute phase of acute coronary syndrome (ACS) does not lower cardiovascular marker levels more than standard therapy, a recent study has found.

Researchers randomly assigned 159 patients to receive either sleep-study guided multidisciplinary therapy (SGMT; n=70; mean age, 55.6±9.0 years; 91.4 percent male) or standard therapy (n=89; mean age, 54.2±7.4 years; 87.6 percent male). The primary study endpoint was the change in plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) levels after 7 months.

NT-proBNP decreased with time in both treatment arms. No significant between-group differences were reported at baseline (579±1,117 vs 611±899 pg/dL; p=0.851) and after 4 (115±222 vs 114±226 pg/dL; p=0.990) and 7 (90±167 vs 93±174 pg/dL; p=0.996) months of follow-up.

Similarly, the magnitudes of change from baseline were comparable between groups after 4 (–464 vs –497 pg/dL; p=0.792) and 7 (–489 vs –518 pg/dL; p=0.726) months.

Levels of plasma suppression of tumorigenicity 2 and high-sensitivity C-reactive protein likewise were not significantly different between the two groups.

These resulted in similar risks. At the 7-month follow-up, the estimated likelihood of developing fatal cardiovascular disease within 10 years was 2.1±1.8 percent in the SGMT group and 2.0±2.4 percent in the controls (p=0.176). At this time point, major adverse cardiac and cerebrovascular events also occurred with comparable frequencies between groups.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
5 days ago
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.